Lipocine Inc. (NASDAQ:LPCN - Get Free Report) CEO Mahesh Patel acquired 25,000 shares of the company's stock in a transaction dated Monday, April 6th. The shares were purchased at an average cost of $2.03 per share, with a total value of $50,750.00. Following the acquisition, the chief executive officer owned 160,679 shares of the company's stock, valued at approximately $326,178.37. This represents a 18.43% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Lipocine Stock Performance
Lipocine stock opened at $1.94 on Tuesday. The firm has a market cap of $14.16 million, a P/E ratio of -1.15 and a beta of 1.09. The business's fifty day moving average is $8.10 and its two-hundred day moving average is $5.78. Lipocine Inc. has a 52 week low of $1.81 and a 52 week high of $12.37.
Lipocine (NASDAQ:LPCN - Get Free Report) last posted its quarterly earnings data on Tuesday, March 10th. The specialty pharmaceutical company reported ($0.34) EPS for the quarter, topping analysts' consensus estimates of ($0.60) by $0.26. The company had revenue of $1.15 million for the quarter, compared to analyst estimates of $0.12 million. Lipocine had a negative return on equity of 59.30% and a negative net margin of 487.00%.
Analyst Upgrades and Downgrades
A number of equities research analysts recently commented on LPCN shares. Wall Street Zen upgraded Lipocine from a "sell" rating to a "hold" rating in a report on Sunday, March 22nd. Weiss Ratings reiterated a "sell (d-)" rating on shares of Lipocine in a report on Friday, March 27th. Finally, HC Wainwright reiterated a "neutral" rating on shares of Lipocine in a report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Lipocine has a consensus rating of "Hold" and an average target price of $15.00.
Get Our Latest Report on LPCN
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of LPCN. Citadel Advisors LLC acquired a new position in shares of Lipocine during the third quarter worth about $41,000. Jane Street Group LLC acquired a new position in shares of Lipocine during the fourth quarter worth about $85,000. Renaissance Technologies LLC boosted its position in shares of Lipocine by 3.6% during the fourth quarter. Renaissance Technologies LLC now owns 37,397 shares of the specialty pharmaceutical company's stock worth $300,000 after buying an additional 1,300 shares during the period. Boothbay Fund Management LLC acquired a new position in shares of Lipocine during the fourth quarter worth about $441,000. Finally, Geode Capital Management LLC boosted its position in shares of Lipocine by 2.2% during the fourth quarter. Geode Capital Management LLC now owns 62,450 shares of the specialty pharmaceutical company's stock worth $502,000 after buying an additional 1,374 shares during the period. 9.11% of the stock is owned by institutional investors and hedge funds.
About Lipocine
(
Get Free Report)
Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company's core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.
The company's lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
